iaintnoangel
Membership Revoked
Thought I would post this after reading the smallpox vaccination scenarios...
http://www.apec.org/infectious/newsbriefs/2002/0005nb10.html
Development of Ebola Vaccine
On 16 May 2002, Crucell NV, a Dutch biotechnology company, announced its collaboration with the US government on the development of a vaccine against Ebola, the filovirus that causes Ebola hemorrhagic fever. The vaccine research center of the National Institutes of Health (NIH), the United States government's major medical research body, has developed Ebola genes that will be used for the vaccine. An experimental vaccine made by the research center succeeded in preventing Ebola in monkeys and the vaccine development will likely be ready for the next stage of development. According to the chief scientific officer at Crucell, the vaccine could be tested in humans within two years and may be available within approximately five or six years. According to Crucell, under the partnership's terms the company will have the option of acquiring exclusive rights to sell the vaccine once it is produced. Under current plans the vaccine will target travelers, government officials, military personnel and people living in Ebola endemic areas.
[Reuters Health Online 05/16/02]
http://www.apec.org/infectious/newsbriefs/2002/0005nb10.html
Development of Ebola Vaccine
On 16 May 2002, Crucell NV, a Dutch biotechnology company, announced its collaboration with the US government on the development of a vaccine against Ebola, the filovirus that causes Ebola hemorrhagic fever. The vaccine research center of the National Institutes of Health (NIH), the United States government's major medical research body, has developed Ebola genes that will be used for the vaccine. An experimental vaccine made by the research center succeeded in preventing Ebola in monkeys and the vaccine development will likely be ready for the next stage of development. According to the chief scientific officer at Crucell, the vaccine could be tested in humans within two years and may be available within approximately five or six years. According to Crucell, under the partnership's terms the company will have the option of acquiring exclusive rights to sell the vaccine once it is produced. Under current plans the vaccine will target travelers, government officials, military personnel and people living in Ebola endemic areas.
[Reuters Health Online 05/16/02]
